Sukyung (Sue) Woo

Contact Information:
Sukyung (Sue) Woo


Woo, Sukyung (HSC)
Assistant Professor

Department of:

College Of Pharmacy/Pharmaceutical Sciences -Assistant Professor

Center of:


State University of New York at Buffalo   Ph.D., (Pharmaceutical Sciences)   2007

Professional Interest/Expertise/Specializations:
Research interests: Preclinical and clinical pharmacokinetic and pharmacodynamic analysis, pharmacogenomics, PK/PD modeling and simulation, systems pharmacology modeling, protein therapeutics, antiangiogenic therapeutics. Dr. Woo's research utilizes quantitative systems pharmacology approaches to guide development of new therapies and potential combination therapies and identification of novel biomarkers for cancer. Quantitative systems pharmacology is integrating systems pharmacology with pharmacokinetics/pharmacodynamics to advance drug discovery and the understanding drug action and holds great promise to facilitate translational research. The research is also focused on investigating how genetic polymorphisms in drug metabolizing enzymes and transporters as well as in drug targets (e.g., ligands, receptors) influence disposition, toxicity, and efficacy of targeted anticancer agents and translating these findings toward personalized medicine.


Research Projects:

"Tumor Resistance Mechanisms to Anti-VEGF Therapy" NIH/NIGMS (COBRE)
ACS Research Scholar GrantFluorescence cytoscopy-photodynamic therapy for early bladder cancer
AAPS New Investigator Grant - Systems Pharmacology Approach for Quantitative Understanding of Treatment Response and Resistance to Anti-angiogenic Agents

Selected Publications:

Quantitative Insight in Utilizing Circulating Angiogenic Factors as Biomarkers for Antiangiogenic Therapy: Systems Pharmacology Approach
2014    Sharan S and Woo S
CPT: Pharmacomet. Syst. Pharmacol 3:e139.
Phase I trial of a new schedule of romidepsin in patients with advanced cancers
2013    Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL
Clin Cancer Res
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
2012    Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.
Clin. Cancer Res.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
   Ning Y, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JM, Lee M, Kim YS, Sun S, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
J Clin Oncol; 28: 2070-2076
Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.
   Mager DM, Woo S, Jusko WJ.
Drug Metabolism and Pharmacokinetics 2009; 24: 16-24.
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
   Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.
Clin Cancer Res 2009; 15: 1496-1503
A Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
   Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Figg WD.
J Clin Pharmacol 2009; 49: 650-660
Methods of utilizing baseline values for indirect response models.
   Woo S, Pawaskar D, Jusko WJ.
J Pharmacokinet Pharmacodyn 2009; 36: 381-405
Pharmacodynamic model for chemotherapy-induced anemia in rats.
   Woo S, Krzyzanski W, Jusko WJ.
Cancer Chemother Pharmacol 2008, 62: 123-133
Population pharmacokinetic and pharmacodynamic modeling of a novel peptidic erythropoiesis receptor agonist (ERA), Hematide, in healthy volunteers.
   Woo S, Krzyzanski W, Duliege A-M, Richard SR, Jusko WJ.
J Clin Pharmacol 2008; 48: 43-52.
Interspecies comparisons of pharmacokinetics and pharmacodynamics of rHuEPO.
   Woo S, Jusko WJ.
Drug Metab Dispos 2007; 35: 1672-1678
Target-mediated pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (rHuEPO).
   Woo S, Krzyzanski W, Jusko WJ.
J Pharmacokinet Pharmacodyn 2007; 34: 849-868.
Pharmacokinetic and pharmacodynamic modeling of rHuEPO after intravenous and subcutaneous administration in rats.
   Woo S, Krzyzanski W, Jusko WJ.
J Pharmacol Exp Ther 2006; 319: 1297-1306.
Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.
   Krzyzanski W, Woo S, Jusko WJ
J Pharmacokinet and Pharmacodyn 2006; 33: 125-165
Vecuronium pharmacokinetics in patients with major burns.
   Vega-Villa K, Kaneda K, Yamashita S, Woo S, Han TH
Br J Anesthesia
A phase I clinical study of high-dose ketoconazole plus weekly docetaxel in metastatic castration-resistant prostate cancer.
   Figg WD, Woo S, Zhu W, Chen X, Ajiboye A, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL.
J Urology; 183: 2219-2226.
Safety and feasibility of long-term intravenous sodium nitrite infusion in health volunteers.
   Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, DeVroom HL, Nahavandi M, Woo S, Figg WD, Lonser RR.
PLoS ONE; 6: e14504
Population pharmacokinetic analysis of sorafenib in patients with solid tumors.
   Jain L, Woo S, Garner ER, Dahut WL, Kohn E, Kummar S, Mould D, Giaccone G, Yarchoan R, Venitz J, Figg WD.
Br J Clin Pharmacol Ther. [Epub ahead of print.]
Impact of ABCB1 allelic variants on QTc interval prolongation.
   Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke RM, Clark JA, Miller-Degraff L, Steinberg SM, Venzon D, Liewehr DJ, Kleeberger SR, Bates SE, Price DK, Rosing R, Cabell C, Sparreboom A, Figg WD.
Clin Cancer Res; 17: 937-946